<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-057081</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Debut of systemic lupus eritematous with castrophic antiphospholipid syndrome: benefit of the early treatment</dc:title>
<dc:description xml:lang="en">The Catastrophic Antiphospholipid Syndrome (CAS) results in multiorgan        system failure. All patients develop occlusive accident in a short        period (days to weeks), with a mortality of 50%. Treatment can include        glucocorticoids, heparin, plasmatic exchange, ciclofosfamide and intravenous        globulin.        The present article treat of female patient lairs Systemic Eritematous        Lupus (SLE), anticardiolipine antibodies, anti ribonucleoprotein antibodies        (antiRNP) and multiorgan systemic failure, she survived thanks to        the multidisciplinary a early treatment</dc:description>
<dc:creator>Huanca Mamani, I</dc:creator>
<dc:creator>Ruiz Domínguez, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La denominación de Síndrome Antifosfolipídico (SAF) &#147;catastrófico&#148;        fue empleada para definir una forma grave y rápidamente evolutiva        de SAF que conduce a fallo multiorgánico. Todos desarrollan accidentes        oclusivos en un corto periodo (días a semanas), siendo el índice de mortalidad        del 50%. En su tratamiento se han utilizado glucocorticoides,        heparina, recambio plasmático, ciclofosfamida y gammaglobulinas intravenosas.        El presente caso es de una paciente de sexo femenino, con diagnóstico        de lupus eritematoso sistémico, con anticuerpos anticardiolipina, anti        ribonucleoproteína (anti RNP) y afectación multiorgánica que sobrevivió        gracias al tratamiento precoz y multidisciplinario</dc:description>
<dc:source>An Med Interna;24(7): 339-341, jul. 2007. ilus</dc:source>
<dc:identifier>ibc-057081</dc:identifier>
<dc:title xml:lang="es">Debut de lupus eritematoso sistémico con síndrome antifosfolipídico catastrófico: beneficio del tratamiento precoz</dc:title>
<dc:subject>^d33768^s22012</dc:subject>
<dc:subject>^d2585^s22012</dc:subject>
<dc:subject>^d9527</dc:subject>
<dc:subject>^d23279^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8356^s22012</dc:subject>
<dc:subject>^d6648^s22073</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d22183^s22073</dc:subject>
<dc:subject>^d2585^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d30257^s22012</dc:subject>
<dc:subject>^d30257^s22067</dc:subject>
<dc:subject>^d5875^s22012</dc:subject>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d5521^s22053</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d1333^s22012</dc:subject>
<dc:subject>^d8356^s22018</dc:subject>
<dc:type>article</dc:type>
<dc:date>200707</dc:date>
</metadata>
</record>
</ibecs-document>
